Clinical Trial

GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity

Recruiting
View on ClinicalTrials.gov →
Summary
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration remain significant concerns. glucagon-like peptide-1 receptor agonists (GLP-1RA) offer distinct advantages for weight loss and metabolic control, and their combination with surgery may produce synergistic effects. This study investigates the efficacy and safety of bariatric surgery combined with adjuvant GLP-1 receptor agonist therapy for Chinese patients with obesity.
Trial Details
NCT Number NCT07633639
Lead Sponsor China-Japan Friendship Hospital
Conditions Obesity
Enrollment 200 participants
Start Date 2026-05-01
Primary Completion 2028-05-01 (estimated)
Study Completion 2028-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-08